Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine

Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine

The coronavirus disease 2019 (COVID-19) pandemic imposes an urgent and continued need for the development of safe and cost-effective vaccines to induce preventive responses for limiting major outbreaks around the world. To combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we repur...

Full description

Bibliographic Details
Main Authors: Almohanad A. Alkayyal, Manar Darwish, Reham Ajina, Saleh Y. Alabbas, Mohammed A. Alotaibi, Abeer Alsofyani, Maha Bokhamseen, Maumonah Hakami, Omar A. Albaradie, Abdulaziz M. Moglan, Sharif Hala, Abdullah Faisal Alsahafi, Samer Zakri, Adnan Almuzaini, Khamis Alsharari, Feras Kaboha, Mustafa Y. Taher, Haggag S. Zein, Fayhan Alroqi, Ahmad Bakur Mahmoud
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Bioengineering and Biotechnology
Subjects:
COVID-19 pandemic
oncolytic virus
repurposing oncolytic virus
VSV∆51M-RBD vaccine
SARS-CoV2 vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fbioe.2023.1150892/full

Internet

https://www.frontiersin.org/articles/10.3389/fbioe.2023.1150892/full

Similar Items